MARKET

MNKD

MNKD

MannKind
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.105
+0.085
+4.21%
Opening 13:47 10/22 EDT
OPEN
2.010
PREV CLOSE
2.020
HIGH
2.131
LOW
1.990
VOLUME
1.91M
TURNOVER
--
52 WEEK HIGH
2.480
52 WEEK LOW
0.8000
MARKET CAP
482.41M
P/E (TTM)
-9.9012
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
MannKind Corporation Participating at Upcoming Conferences
WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at upcoming conferences
GlobeNewswire · 09/08 13:00
Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety
WESTLAKE VILLAGE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman, MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKind’s medical affairs, field medical activities
GlobeNewswire · 08/31 14:00
Key Things To Understand About MannKind's (NASDAQ:MNKD) CEO Pay Cheque
Simply Wall St. · 08/24 19:28
MannKind (MNKD) in Focus: Stock Moves 8.7% Higher
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Zacks · 08/20 13:39
MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020
GlobeNewswire · 08/07 22:00
MannKind Corporation's (MNKD) CEO Michael Castagna on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/06 03:19
MannKind (MNKD) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 08/05 23:35
MannKind Corporation Reports 2020 Second Quarter Financial Results
GlobeNewswire · 08/05 21:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MNKD. Analyze the recent business situations of MannKind through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MNKD stock price target is 3.000 with a high estimate of 4.000 and a low estimate of 2.500.
EPS
Institutional Holdings
Institutions: 193
Institutional Holdings: 76.82M
% Owned: 33.52%
Shares Outstanding: 229.17M
TypeInstitutionsShares
Increased
50
11.09M
New
44
9.94M
Decreased
18
1.84M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.14%
Pharmaceuticals & Medical Research
+0.13%
Key Executives
Chairman/Independent Director
Kent Kresa
Chief Executive Officer/Director
Michael Castagna
Chief Financial Officer
Steven Binder
Chief Human Resource Officer
Stuart Tross
Executive Vice President/General Counsel/Secretary
David Thomson
Chief Technology Officer
Joseph Kocinsky
Vice President/Controller/Treasurer/Director of Investor Relations
Rosabel Alinaya
Other
Patrick McCauley
Vice President
Kevin Kaiserman
Independent Director
Ronald Consiglio
Independent Director
Michael Friedman
Independent Director
Jennifer Grancio
Independent Director
Anthony Hooper
Independent Director
Christine Mundkur
Independent Director
James Shannon
Independent Director
David Maccallum
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MNKD
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of MannKind Corporation stock information, including NASDAQ:MNKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNKD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNKD stock methods without spending real money on the virtual paper trading platform.